X

Indication

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia... read more

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis. read more

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis.

Limitations of Use

  • Aranesp® has not been shown to improve quality of life, fatigue, or patient well-being.
  • Aranesp® is not indicated for use as a substitute for red blood cell transfusions in patients who require immediate correction of anemia.
› Email› Print

Amgen Anemia Management Institute™ (AAMI)

Available on the Anemia Hub™ from Amgen!

The Anemia Hub™ provides access to the AAMI programs and the Pathophysiology of Anemia Due to Chronic Kidney Disease video series.

Introducing Anemia Hub™ from Amgen

From interactive programs that address key aspects of anemia management to the latest trends data peer polls, and more, Anemia Hub™ puts the information at your fingertips.